Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 18/20 | 1.00 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12660570 | 1.00 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| SCHEMBL6235224 | 1.00 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| SCHEMBL6352708 | 1.00 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| SCHEMBL6239907 | 0.90 | MAPKAPK2 (0.82) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| SCHEMBL1491372 | 0.89 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| SCHEMBL6239836 | 0.89 | MAPKAPK2 (0.80) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| Hydrochloric Acid SCHEMBL6358190 | 0.89 | MAPKAPK2 (0.80) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| Hydrochloric Acid SCHEMBL6352215 | 0.88 | MAPKAPK2 (0.98) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| SCHEMBL6241595 | 0.88 | MAPKAPK2 (0.79) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B | |
| SCHEMBL6241157 | 0.87 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5ALDH1A1MAPTHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | claimed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | claimed |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-10-09 | — | — | US | claimed |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | claimed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | claimed |
| US-20080187572-A1 | Matrix Metalloproteinase Inhibitors of Tgfb-Induced Subcapsular Cataract Formation | MCMASTER UNIVERSITY (CA) | 2008-08-07 | — | — | US | claimed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | claimed |
| EP-0891187-B1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | claimed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | claimed |
| EP-0891187-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-20 | — | — | EP | claimed |
| WO-1997037658-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 1997-10-16 | — | — | WO | claimed |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| EP-3965738-B1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIV DO MINHO (PT) | 2025-08-06 | — | — | EP | disclosed |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-11-28 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060405-A2 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060424-A2 | SILK-CONTAINING STENT GRAFT | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| EP-0891187-B1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | disclosed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885MAPKAPK5 34/4885ALDH1A1 4386/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | MAPKAPK2 3624/4885MAPKAPK5 3577/4885ALDH1A1 371/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | MAPKAPK2 3175/4885MAPKAPK5 3524/4885ALDH1A1 1257/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | MAPKAPK2 3520/4885MAPKAPK5 3279/4885ALDH1A1 460/4885 |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | INMT, HNMT, CPT1A | MAPKAPK2 3520/4885MAPKAPK5 3279/4885ALDH1A1 460/4885 |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | MAPKAPK2 3472/4885MAPKAPK5 3040/4885ALDH1A1 320/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | MAPKAPK2 3624/4885MAPKAPK5 3577/4885ALDH1A1 371/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | MAPKAPK2 3119/4885MAPKAPK5 3238/4885ALDH1A1 1381/4885 |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | MAVS, IDO2, IDO1 | MAPKAPK2 2904/4885MAPKAPK5 3469/4885ALDH1A1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.